That's fine. That's all I needed to hear to confirm, but this just seems tragic in a time of a trade war. We're trying to buy Canadian and support Canadian industries, and I have all these entrepreneurs coming into my office and having to hire lobbyists to come and tell me about how we're chasing them out of the country. Then that same entrepreneur, once chased out into the United States, can sell me their product on Amazon. If that's the ultimate outcome of the 2023 changes, that's just a crying shame. I hope the members opposite will take that into account.
Here's one, I guess, factoid.
I'm a physician. I specialize in critical care and internal medicine. I would say that two or three times a week throughout my career, I would admit someone to the hospital, sometimes with a deathly illness caused by an adverse reaction to a pharmaceutical product, but I can't think of one time in my career when I've had someone come in with a deadly or near-fatal reaction to a natural health product.
My colleague Dr. Eyolfson spoke about St. John's wort. I've personally admitted hundreds of SSRI overdoses to the hospital. I've not ever seen one hospital admission from St. John's wort in my life, nor have I heard of one from my colleagues.
Would you agree that this is a different class of risk, empirically, and therefore should have a different class or a different intensity of regulation?
